In its May 2024 meeting, the European Medicines Agency (EMA) gave the go-ahead for Durveqtix to treat severe and moderately severe hemophilia B in adults who do not have factor IX inhibitors or detectable antibodies to variant adeno-associated virus serotype Rh74 (AAVRh74var). The agency has also recommended Adzynma for the treatment of ADAMTS13 enzyme deficiency …
